4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
12.19
+0.54 (4.64%)
At close: Aug 14, 2026, 4:00 PM EDT
12.19
0.00 (0.00%)
After-hours: Aug 14, 2026, 4:20 PM EDT

4D Molecular Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
92.0185.210.0420.723.1318.04
Revenue Growth
278712.12%230194.59%-99.82%562.29%-82.65%32.52%
Cost of Revenue
192.5192.5141.397.180.2561.36
Gross Profit
-100.49-107.29-141.26-76.37-77.12-43.32
Selling, General & Admin
48.8249.0646.5836.4932.9128.01
Operating Expenses
93.4349.0646.5836.4932.9128.01
Operating Income
-193.92-156.35-187.84-112.87-110.03-71.33
Interest & Investment Income
18.1519.4827.0512.212.570.14
Other Non Operating Income (Expenses)
-0.21-0.04-0.08-0.18-0.04-0.12
EBT Excluding Unusual Items
-175.98-136.91-160.87-100.84-107.49-71.32
Merger & Restructuring Charges
-3.2-3.2----
Pretax Income
-179.18-140.11-160.87-100.84-107.49-71.32
Net Income
-179.18-140.11-160.87-100.84-107.49-71.32
Net Income to Common
-179.18-140.11-160.87-100.84-107.49-71.32
Net Income Growth
------
Shares Outstanding (Basic)
655854393228
Shares Outstanding (Diluted)
655854393228
Shares Change
15.93%7.39%37.86%20.95%16.66%331.23%
EPS (Basic)
-2.77-2.42-2.98-2.58-3.32-2.57
EPS (Diluted)
-2.77-2.42-2.98-2.58-3.32-2.57
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-155.97-109.62-138.37-78.56-98.22-78.24
Free Cash Flow Per Share
-2.41-1.89-2.56-2.01-3.04-2.82
Gross Margin
-109.22%-125.91%----240.17%
Operating Margin
-210.76%-183.49%-507678.38%-544.65%-3516.52%-395.46%
Profit Margin
-194.74%-164.43%-434778.38%-486.59%-3435.41%-395.37%
Free Cash Flow Margin
-169.51%-128.65%-373975.68%-379.11%-3139.05%-433.77%
EBITDA
-188.89-151.65-183.19-108.66-107.63-69.81
EBITDA Margin
-205.30%-177.98%----
D&A For EBITDA
5.034.694.654.22.41.52
EBIT
-193.92-156.35-187.84-112.87-110.03-71.33
EBIT Margin
-210.76%-183.49%----
SEC Filings: 10-K · 10-Q